Home > Coller Institute News > Call for Papers on Deep Innovation 征稿:关于深度创新的最新发展

Call for Papers on Deep Innovation 征稿:关于深度创新的最新发展


CIV is now – until August 8th – accepting proposals for commissioned papers for the next issue of Coller Venture Review, focused on Deep Innovation.

To find out how you (or a relevant colleague) can contribute, contact Nathan Zeldes.

Deep Innovation is defined as inventions that stem from basic research or a scientific breakthrough. Unlike what we see in the ubiquitous Internet/Cyber/IT startups, deep innovation endeavors usually entail substantial resources and time to materialize (typically $10–100M and 5–20 years).

Notable examples can be found in the domains of:

  • Water Venture (see our workshop on this subject)
  • Nanotechnology (see lectures here)
  • Brain-tech (and here)
  • Materials
  • Food-tech
  • Name your own domain…

Learn more about Deep Innovation here.

Authors who contribute to Coller Venture Review, our flagship publication, have the opportunity to expose their thoughts to thousands of stakeholders in the Venture ecosystem.

Past issues of Coller Venture Review focused on Policy, and History of Venture. Sample articles from previous issues include: The Public Venture Policy Menu Apple’s DNA, and Key Insights From a Century of Venture.

Deep Innovation papers could address:

  • Challenges and solutions related to commercializing Deep Innovation;
  • Methodologies that can help such basic research cross over into successful businesses;
  • Case studies of actual implementations.

If interested, please contact our Associate Editor Nathan Zeldes, by August 8th, 2015.

Check Also

Structured Exits: A Potential New Source of Funding for Life Science Startups A Guest Post by Leslie Mitts

Structured exits are an important funding structure for new ventures. Rather than relying solely on the upside from an exit, structured exits can rely on the venture’s anticipated cash flow, or percentage of milestone payments, to repay the investor. For investors, they can offer reduced risk with the possibility of an upside; for ventures, they provide a new source of growth capital and less dilution. For life-sciences companies caught in the “death valley” between seed grants and venture capital eligibility, structured exits - carefully adapted and applied - can be a new alternative or complement to bridge loans, incubators, strategic investors, and non-dilutive funding from government sources. Read more in a guest post by Leslie Mitts, featuring Att. David Gitlin, on the CIV website.